Lymphoma, Non-Hodgkin
Information
- Disease name
- Lymphoma, Non-Hodgkin
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04772989 | Active, not recruiting | Phase 1 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | March 19, 2021 | September 2025 |
| NCT04860466 | Active, not recruiting | Phase 1 | A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | January 20, 2022 | August 20, 2025 |
| NCT04210219 | Active, not recruiting | Phase 1 | A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | July 2, 2020 | April 6, 2026 |
| NCT05024045 | Active, not recruiting | Phase 1 | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | September 30, 2021 | December 2024 |
| NCT04089215 | Active, not recruiting | Phase 2 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma | June 11, 2019 | September 30, 2024 |
| NCT03900598 | Active, not recruiting | Phase 1 | A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | April 3, 2019 | January 30, 2026 |
| NCT03480360 | Active, not recruiting | Phase 3 | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | March 28, 2018 | September 13, 2025 |
| NCT03366272 | Active, not recruiting | Phase 2/Phase 3 | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients | December 5, 2017 | November 2024 |
| NCT06170216 | Active, not recruiting | Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL) | January 10, 2023 | January 10, 2026 | |
| NCT03301168 | Active, not recruiting | Phase 1/Phase 2 | Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant | April 2014 | May 2034 |
| NCT04657224 | Active, not recruiting | Phase 1 | A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | February 25, 2021 | July 11, 2025 |
| NCT04540796 | Active, not recruiting | Phase 1 | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | November 20, 2020 | May 9, 2025 |
| NCT00368082 | Active, not recruiting | Phase 1 | Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) | April 2006 | July 2031 |
| NCT03220347 | Active, not recruiting | Phase 1 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas | July 24, 2017 | June 15, 2026 |
| NCT02663297 | Active, not recruiting | Phase 1 | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | July 15, 2016 | January 2037 |
| NCT04876092 | Active, not recruiting | Phase 1 | A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL | July 28, 2021 | November 25, 2024 |
| NCT04434196 | Active, not recruiting | Phase 1 | A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | December 21, 2020 | May 13, 2025 |
| NCT04849416 | Active, not recruiting | Phase 2 | A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) | May 14, 2021 | April 19, 2025 |
| NCT05784415 | Active, not recruiting | Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell | February 16, 2021 | August 31, 2025 | |
| NCT01996865 | Active, not recruiting | Phase 3 | Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. | April 1, 2014 | July 8, 2024 |
| NCT00579163 | Active, not recruiting | Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | December 1994 | December 2024 | |
| NCT00882895 | Active, not recruiting | Phase 2 | Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma | May 5, 2009 | June 1, 2028 |
| NCT04245839 | Active, not recruiting | Phase 2 | A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) | July 14, 2020 | September 28, 2028 |
| NCT00103610 | Completed | Phase 3 | Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients | January 2005 | December 2007 |
| NCT00114348 | Completed | Phase 4 | ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia | August 2003 | July 2012 |
| NCT00117156 | Completed | Phase 2 | Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma | December 2003 | January 2012 |
| NCT00141297 | Completed | Phase 1 | A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer | September 2004 | December 2014 |
| NCT00145613 | Completed | Phase 2 | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | June 2003 | February 2009 |
| NCT00156013 | Completed | Phase 1/Phase 2 | Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) | September 2005 | April 2010 |
| NCT00168727 | Completed | Phase 4 | Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma | June 1, 2003 | October 31, 2005 |
| NCT00185393 | Completed | Phase 3 | Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy | August 2001 | February 2007 |
| NCT00185731 | Completed | Phase 2 | Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma | April 2005 | November 2012 |
| NCT00186290 | Completed | N/A | Allo BMT in Advanced Leukemia or High Grade Lymphoma | December 1989 | October 2009 |
| NCT00186355 | Completed | N/A | Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma | October 2003 | February 2010 |
| NCT00186394 | Completed | Phase 2 | High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma | April 2000 | December 2006 |
| NCT00186589 | Completed | Phase 1 | 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL | May 2004 | July 2007 |
| NCT00187070 | Completed | N/A | Large Cell Lymphoma Pilot Study III | December 1997 | July 2001 |
| NCT00188370 | Completed | Phase 2 | Ultrasound Biomicroscopy - Apoptosis | April 1999 | December 2004 |
| NCT00188929 | Completed | Phase 2 | Assessment of Treatment Response Using PET/CT Scanner - Non Hodgkin's Lymphoma | August 2005 | July 2009 |
| NCT00232440 | Completed | Phase 1/Phase 2 | Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma | January 2003 | June 2009 |
| NCT00240565 | Completed | Phase 2 | Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma | April 2004 | September 2011 |
| NCT00240578 | Completed | Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab | November 2003 | June 2013 | |
| NCT00240591 | Completed | Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab | October 2003 | June 2010 | |
| NCT00241358 | Completed | Phase 1/Phase 2 | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies | May 2004 | February 2010 |
| NCT00261677 | Completed | Phase 3 | A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy | August 2000 | October 2003 |
| NCT00268203 | Completed | Phase 2 | Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma | September 1998 | February 2013 |
| NCT00268983 | Completed | Phase 3 | Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma | October 2004 | June 2013 |
| NCT00283985 | Completed | Phase 2 | Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma | February 2006 | June 2012 |
| NCT00322387 | Completed | Phase 2 | Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients | April 2004 | July 2006 |
| NCT00322491 | Completed | Phase 2 | Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | March 2004 | June 2006 |
| NCT00322842 | Completed | Phase 2 | Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | September 2004 | February 2007 |
| NCT00329030 | Completed | Phase 3 | Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) | December 2005 | August 2013 |
| NCT00339963 | Completed | Genome Expression in Lymphoma, Leukemia and Multiple Myeloma | November 9, 2001 | ||
| NCT00347971 | Completed | Phase 1 | Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma | June 2006 | April 2008 |
| NCT00350181 | Completed | Phase 2 | Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT | August 2006 | April 2010 |
| NCT00396266 | Completed | Phase 2 | AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF | January 2005 | December 2007 |
| NCT00398372 | Completed | N/A | Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment | November 2000 | September 2009 |
| NCT00412321 | Completed | Phase 1 | A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease | May 2005 | April 2011 |
| NCT00426855 | Completed | Phase 1/Phase 2 | Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) | January 2007 | June 2009 |
| NCT00430846 | Completed | Phase 1 | Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies | November 2006 | July 2009 |
| NCT00435916 | Completed | Phase 2 | Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma | December 2006 | January 2009 |
| NCT00500058 | Completed | Phase 1 | A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 | July 31, 2007 | March 4, 2010 |
| NCT00534820 | Completed | N/A | Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | June 2004 | August 2013 |
| NCT00534989 | Completed | N/A | Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT | September 2007 | December 2013 |
| NCT00536835 | Completed | Phase 1 | Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma | August 16, 2007 | September 29, 2009 |
| NCT00546793 | Completed | Phase 1/Phase 2 | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL | January 2008 | March 2013 |
| NCT00553943 | Completed | Phase 2 | Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis | July 2007 | March 2017 |
| NCT00562224 | Completed | Phase 1 | Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients | November 2007 | September 2010 |
| NCT00572637 | Completed | Phase 1 | Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas | November 2007 | March 2010 |
| NCT00644124 | Completed | Phase 1 | Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma | March 2008 | October 2011 |
| NCT00000658 | Completed | Phase 3 | A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma | February 1996 | |
| NCT00000689 | Completed | Phase 1 | Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma | March 1991 | |
| NCT00000703 | Completed | N/A | Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members | March 1990 | |
| NCT00000801 | Completed | Phase 2 | Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma | April 1998 | |
| NCT00001120 | Completed | A Study of Patients With AIDS Syndrome | |||
| NCT00001301 | Completed | Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors | August 1992 | April 2000 | |
| NCT00001571 | Completed | A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines | February 1997 | December 2000 | |
| NCT00001575 | Completed | Phase 1/Phase 2 | Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia | April 1997 | November 2013 |
| NCT00002003 | Completed | Phase 2 | Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas | ||
| NCT00002221 | Completed | Phase 2 | Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma | ||
| NCT00002284 | Completed | N/A | A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant | ||
| NCT00002348 | Completed | Phase 2 | A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma | ||
| NCT00006434 | Completed | Phase 3 | Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma | ||
| NCT00025662 | Completed | Phase 2 | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | May 2001 | February 2008 |
| NCT00044551 | Completed | Phase 2 | Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma | February 2002 | July 2003 |
| NCT00045864 | Completed | Phase 2 | Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma. | ||
| NCT00045877 | Completed | Phase 2/Phase 3 | Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments | ||
| NCT00061672 | Completed | Phase 2 | Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma | April 2003 | |
| NCT00067002 | Completed | Phase 2 | Randomized Double Cord Blood Transplant Study | April 2003 | July 2016 |
| NCT00067288 | Completed | Phase 2 | Meaning-Centered Psychotherapy in Advanced Cancer | May 2002 | March 2006 |
| NCT00082303 | Completed | Phase 1/Phase 2 | Music Imagery for Patients Receiving Chemotherapy for Leukemia or Non-Hodgkin's Lymphoma | July 2002 | |
| NCT00088530 | Completed | Phase 3 | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | July 2004 | July 2010 |
| NCT00094848 | Completed | Phase 2 | Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | June 2004 | May 2007 |
| NCT00655837 | Completed | Phase 1 | Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL | April 2008 | February 2010 |
| NCT00724984 | Completed | Phase 1/Phase 2 | Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma | July 2008 | |
| NCT00733824 | Completed | Phase 1/Phase 2 | Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma | November 2008 | September 2013 |
| NCT00779584 | Completed | Phase 1 | A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) | October 17, 2008 | May 28, 2011 |
| NCT00862719 | Completed | Phase 2 | Sitagliptin Umbilical Cord Blood Transplant Study | March 2009 | February 2015 |
| NCT00866047 | Completed | Phase 2 | A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma | March 2009 | June 2016 |
| NCT00871663 | Completed | Phase 1 | Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) | August 2006 | October 2012 |
| NCT00871702 | Completed | Phase 1 | Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease | October 2010 | November 2012 |
| NCT00871910 | Completed | Phase 1 | Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) | October 11, 2006 | February 22, 2010 |
| NCT00880581 | Completed | Phase 2 | A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas | January 2009 | January 2015 |
| NCT00896493 | Completed | Phase 2 | Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma | May 2009 | December 2022 |
| NCT00901069 | Completed | Phase 1 | Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma | May 2009 | November 2012 |
| NCT00903890 | Completed | Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma | August 2008 | April 9, 2020 | |
| NCT00912223 | Completed | Phase 2 | Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) | April 2009 | August 2016 |
| NCT00933335 | Completed | Phase 2 | Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab | August 1998 | August 2010 |
| NCT00938041 | Completed | Phase 2 | Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody | April 1998 | June 2013 |
| NCT00947856 | Completed | Phase 2 | A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study | July 2009 | March 2013 |
| NCT00950755 | Completed | Phase 2 | Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology | June 1998 | April 2011 |
| NCT00989664 | Completed | Phase 2 | Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma | November 1996 | September 2008 |
| NCT00992758 | Completed | Phase 1 | Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement | May 28, 1999 | June 7, 2012 |
| NCT00996593 | Completed | Phase 2 | Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab | July 1998 | August 2009 |
| NCT00996996 | Completed | Phase 2 | Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma | June 1996 | October 2011 |
| NCT01015911 | Completed | Phase 1 | A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma | November 2009 | March 2012 |
| NCT01026233 | Completed | Phase 1 | Cardiac Safety Study of Brentuximab Vedotin (SGN-35) | January 2010 | August 2011 |
| NCT01026415 | Completed | Phase 1 | Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | December 2009 | May 2012 |
| NCT01135849 | Completed | B-Receptor Signaling in Cardiomyopathy | November 2008 | October 2010 | |
| NCT01155817 | Completed | Phase 1 | Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease | August 2010 | December 2013 |
| NCT01158118 | Completed | Phase 2 | Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors | April 1, 2011 | December 31, 2016 |
| NCT01196520 | Completed | Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM) | May 25, 2010 | May 21, 2020 | |
| NCT01224821 | Completed | Phase 2 | Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies | December 1995 | May 2008 |
| NCT01294579 | Completed | Phase 2 | Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) | May 17, 2011 | December 20, 2016 |
| NCT01307267 | Completed | Phase 1 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | June 21, 2011 | February 20, 2019 |
| NCT01403948 | Completed | Phase 1 | BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) | August 1, 2011 | February 28, 2018 |
| NCT01410630 | Completed | FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma | September 7, 2017 | October 4, 2019 | |
| NCT01421667 | Completed | Phase 2 | A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | August 2011 | June 2015 |
| NCT01534715 | Completed | Phase 1 | IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | January 2012 | July 2016 |
| NCT01536561 | Completed | Phase 1 | Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma | April 24, 1990 | October 16, 2009 |
| NCT01573000 | Completed | Phase 2 | A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL) | September 1998 | April 2010 |
| NCT01584141 | Completed | Study of Lymphoma in Asia | July 5, 2011 | July 10, 2018 | |
| NCT01660451 | Completed | Phase 2 | Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas | November 19, 2012 | May 18, 2023 |
| NCT01660607 | Completed | Phase 1/Phase 2 | Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell | December 2011 | December 20, 2023 |
| NCT01663714 | Completed | Phase 2 | Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma. | February 2000 | February 2012 |
| NCT01720264 | Completed | Phase 2 | Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant | November 2, 2012 | December 15, 2017 |
| NCT01754857 | Completed | Phase 2 | Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL | November 12, 2013 | June 30, 2022 |
| NCT01866839 | Completed | Phase 1/Phase 2 | Preventing Stem Cell Transplant Complications With a Blood Separator Machine | May 29, 2013 | June 28, 2018 |
| NCT01868035 | Completed | Phase 2 | Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP | May 2000 | October 2012 |
| NCT01938001 | Completed | Phase 3 | Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) | November 21, 2013 | January 26, 2022 |
| NCT01969435 | Completed | Phase 2 | Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma | March 19, 2014 | May 31, 2017 |
| NCT02055820 | Completed | Phase 1/Phase 2 | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL | November 17, 2013 | June 28, 2019 |
| NCT02072967 | Completed | Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma | May 2012 | October 2015 | |
| NCT02098109 | Completed | Phase 2 | Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | August 20, 2014 | September 18, 2016 |
| NCT02187133 | Completed | Phase 1 | Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | May 5, 2015 | March 31, 2021 |
| NCT02257242 | Completed | Phase 1 | Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma | May 10, 2017 | November 18, 2020 |
| NCT02369016 | Completed | Phase 3 | Phase III Copanlisib in Rituximab-refractory iNHL | September 22, 2015 | October 26, 2022 |
| NCT02389101 | Completed | N/A | Molecular and Whole-body MR Imaging in Lymphomas | October 2014 | September 2016 |
| NCT02417285 | Completed | Phase 1 | A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. | May 22, 2015 | September 28, 2023 |
| NCT02434484 | Completed | Symbenda Post-Marketing Surveillance (PMS) | July 4, 2018 | March 20, 2020 | |
| NCT02499003 | Completed | Phase 2 | GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma | August 14, 2015 | January 2, 2022 |
| NCT02509039 | Completed | Phase 1 | A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | September 2, 2015 | May 9, 2023 |
| NCT02581878 | Completed | Phase 1 | Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma | November 20, 2015 | November 26, 2019 |
| NCT02613598 | Completed | Phase 1 | Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma | May 12, 2016 | June 7, 2021 |
| NCT02747043 | Completed | Phase 3 | Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab | May 25, 2016 | June 28, 2019 |
| NCT03019055 | Completed | Phase 1 | Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell | October 16, 2017 | August 24, 2021 |
| NCT03052777 | Completed | N/A | Using Telephone Counselling to Improve Exercise Participation in Hematologic Cancer Survivors | February 21, 2017 | August 1, 2017 |
| NCT03057418 | Completed | Phase 1 | Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim | June 2013 | December 2016 |
| NCT03188354 | Completed | N/A | Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma | November 1, 2017 | December 31, 2023 |
| NCT03289182 | Completed | An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) | September 15, 2017 | October 27, 2020 | |
| NCT03310619 | Completed | Phase 1/Phase 2 | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | December 20, 2017 | February 15, 2023 |
| NCT03357627 | Completed | Phase 1 | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma | February 16, 2018 | August 3, 2021 |
| NCT03480087 | Completed | Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma | January 2015 | July 2022 | |
| NCT03483103 | Completed | Phase 2 | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) | July 27, 2018 | December 1, 2022 |
| NCT03484702 | Completed | Phase 2 | Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma | September 7, 2018 | December 15, 2023 |
| NCT03498430 | Completed | Phase 1 | Copanlisib Chinese PK Study | April 27, 2018 | June 2, 2020 |
| NCT03575351 | Completed | Phase 3 | A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas | October 23, 2018 | October 23, 2023 |
| NCT03682796 | Completed | Phase 1 | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma | October 15, 2018 | November 17, 2021 |
| NCT03743246 | Completed | Phase 1/Phase 2 | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | October 17, 2018 | January 26, 2024 |
| NCT03744676 | Completed | Phase 2 | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | November 29, 2018 | September 22, 2023 |
| NCT04030195 | Completed | Phase 1/Phase 2 | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | March 24, 2020 | June 24, 2021 |
| NCT04052126 | Completed | N/A | An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic Malignancies | November 28, 2019 | May 30, 2023 |
| NCT04089527 | Completed | Phase 1 | Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma | October 24, 2019 | October 25, 2021 |
| NCT04136275 | Completed | Phase 1 | CAR-37 T Cells In Hematologic Malignancies | June 19, 2020 | March 1, 2024 |
| NCT04971304 | Completed | Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars | March 1, 2015 | December 31, 2022 | |
| NCT05131815 | Completed | N/A | The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors | January 10, 2022 | August 21, 2023 |
| NCT05176873 | Completed | Phase 1 | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants | December 9, 2021 | May 22, 2022 |
| NCT05188755 | Completed | N/A | Fitness Assessment in Young Adults Recovered From Lymphoma | January 1, 2022 | December 6, 2022 |
| NCT06190457 | Completed | Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma | September 30, 2015 | August 30, 2022 | |
| NCT05332054 | Enrolling by invitation | Long-Term Follow-up Study | March 16, 2022 | December 2041 | |
| NCT03229200 | Enrolling by invitation | Phase 4 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | May 22, 2017 | July 2, 2027 |
| NCT04911478 | Enrolling by invitation | Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells | February 14, 2022 | August 2039 | |
| NCT04996706 | Enrolling by invitation | Lymphoma Epidemiology of Outcomes Cohort Years 6-10 | August 16, 2021 | August 1, 2026 | |
| NCT01196208 | No longer available | A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 | |||
| NCT06343311 | Not yet recruiting | Phase 1/Phase 2 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | June 15, 2024 | December 31, 2027 |
| NCT06133426 | Not yet recruiting | N/A | Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients | May 2024 | September 2024 |
| NCT06458439 | Not yet recruiting | Phase 2 | Epcoritamab-CAR T Cells for Large B-cell Lymphomas | July 2024 | December 2027 |
| NCT06101381 | Not yet recruiting | Phase 1/Phase 2 | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma | October 2023 | October 2028 |
| NCT05824585 | Not yet recruiting | Phase 1 | DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | April 2023 | October 30, 2027 |
| NCT02497898 | Not yet recruiting | Phase 2 | Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma | July 2015 | July 2040 |
| NCT06427213 | Not yet recruiting | Phase 2 | This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma | May 20, 2024 | December 30, 2029 |
| NCT04935684 | Recruiting | Phase 2 | Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation | December 20, 2022 | December 2027 |
| NCT05153330 | Recruiting | Phase 1 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | January 24, 2022 | March 31, 2025 |
| NCT05618366 | Recruiting | Phase 1 | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | June 7, 2023 | December 2028 |
| NCT00398177 | Recruiting | Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease | January 1999 | January 2099 | |
| NCT04460235 | Recruiting | Phase 4 | Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma | September 9, 2021 | June 2026 |
| NCT05424822 | Recruiting | Phase 1 | A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | August 18, 2022 | October 30, 2026 |
| NCT04637763 | Recruiting | Phase 1 | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | May 26, 2021 | September 2025 |
| NCT04892667 | Recruiting | N/A | Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG | April 1, 2022 | October 2024 |
| NCT05150405 | Recruiting | Phase 1 | A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors | October 19, 2021 | June 1, 2024 |
| NCT05219513 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | February 18, 2022 | April 30, 2025 |
| NCT04735471 | Recruiting | Phase 1 | A Phase 1 Study of ADI-001 in B Cell Malignancies | March 4, 2021 | December 31, 2027 |
| NCT01676805 | Recruiting | Tissue Collection for Studies of Lymph Cancer | September 21, 2012 | ||
| NCT03448393 | Recruiting | Phase 1 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | March 26, 2018 | December 31, 2040 |
| NCT05255601 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | September 13, 2022 | July 5, 2028 |
| NCT02682667 | Recruiting | Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols | April 11, 2016 | December 1, 2027 | |
| NCT05800210 | Recruiting | Phase 2 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | May 3, 2024 | May 2027 |
| NCT05844956 | Recruiting | Phase 1/Phase 2 | A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | June 1, 2022 | October 30, 2027 |
| NCT05968963 | Recruiting | N/A | Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation | November 28, 2023 | August 1, 2024 |
| NCT03598608 | Recruiting | Phase 1/Phase 2 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | October 17, 2018 | April 19, 2028 |
| NCT06022029 | Recruiting | Phase 1 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | October 13, 2023 | August 29, 2026 |
| NCT00626496 | Recruiting | Family Study of Lymphoproliferative Disorders | April 1, 2004 | December 31, 2029 | |
| NCT02690545 | Recruiting | Phase 1/Phase 2 | Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | August 26, 2016 | August 26, 2040 |
| NCT06045910 | Recruiting | Phase 1/Phase 2 | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | January 19, 2024 | December 2027 |
| NCT05025358 | Recruiting | Phase 1 | A Study of LP-118 in Patients With Advanced Tumors | September 14, 2021 | July 30, 2024 |
| NCT05020678 | Recruiting | Phase 1 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | August 20, 2021 | December 2038 |
| NCT05442515 | Recruiting | Phase 1/Phase 2 | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | December 28, 2022 | July 1, 2029 |
| NCT03930953 | Recruiting | Phase 1/Phase 2 | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) | May 20, 2019 | April 18, 2027 |
| NCT05515406 | Recruiting | Phase 1 | A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL | February 13, 2023 | December 2027 |
| NCT03958916 | Recruiting | Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL | May 5, 2017 | May 5, 2025 | |
| NCT03971318 | Recruiting | A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBL | May 5, 2017 | May 5, 2025 | |
| NCT06120504 | Recruiting | Phase 1 | A Safety Study of SGN-35T in Adults With Advanced Cancers | February 29, 2024 | April 30, 2030 |
| NCT03117036 | Recruiting | Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III | March 1, 2017 | December 28, 2026 | |
| NCT04077723 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | August 13, 2019 | March 31, 2025 |
| NCT04982471 | Recruiting | Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study | November 5, 2021 | July 30, 2029 | |
| NCT05540340 | Recruiting | N/A | A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant | September 9, 2022 | September 2024 |
| NCT02693535 | Recruiting | Phase 2 | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | March 14, 2016 | December 31, 2025 |
| NCT04975555 | Recruiting | Phase 2 | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | November 15, 2021 | December 31, 2025 |
| NCT06139406 | Recruiting | Phase 1 | A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer | December 6, 2023 | July 8, 2026 |
| NCT04090268 | Recruiting | N/A | Precision Exercise in Children With Malignant Hemopathies | April 3, 2017 | April 3, 2026 |
| NCT05556720 | Recruiting | Phase 3 | Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial | December 1, 2022 | December 31, 2025 |
| NCT06149169 | Recruiting | Phase 2 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma | August 17, 2023 | March 31, 2025 |
| NCT03297606 | Recruiting | Phase 2 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | March 23, 2018 | January 31, 2027 |
| NCT02602067 | Terminated | Phase 1 | 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients | November 2015 | April 30, 2017 |
| NCT02626455 | Terminated | Phase 3 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) | January 6, 2016 | November 10, 2023 |
| NCT02703272 | Terminated | Phase 3 | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma | July 1, 2016 | June 11, 2021 |
| NCT02867618 | Terminated | Phase 1/Phase 2 | Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma | October 16, 2016 | June 30, 2020 |
| NCT02875223 | Terminated | Phase 1 | A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | August 31, 2016 | March 25, 2024 |
| NCT02954406 | Terminated | Phase 1 | A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma | March 5, 2017 | July 27, 2020 |
| NCT03238651 | Terminated | Phase 1 | A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) | August 1, 2017 | August 17, 2020 |
| NCT00529503 | Terminated | Phase 2 | A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL | September 2007 | May 2011 |
| NCT00490490 | Terminated | Phase 2 | Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy | January 2007 | July 2013 |
| NCT00649584 | Terminated | Phase 1 | A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies | March 2008 | February 2010 |
| NCT00147485 | Terminated | Phase 1 | A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer | December 2004 | August 2007 |
| NCT00482053 | Terminated | Phase 2 | Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT | October 2006 | May 2010 |
| NCT03733249 | Terminated | Phase 1/Phase 2 | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | January 2017 | April 14, 2023 |
| NCT00916045 | Terminated | Phase 2 | Pilot Study of Unrelated Cord Blood Transplantation | September 2009 | March 2012 |
| NCT00481832 | Terminated | Phase 2 | Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma | January 2007 | March 30, 2017 |
| NCT00963495 | Terminated | Phase 1 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | August 2009 | September 2013 |
| NCT04074330 | Terminated | Phase 1/Phase 2 | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma | October 15, 2019 | April 26, 2023 |
| NCT01045382 | Terminated | Phase 2 | MSC and HSC Coinfusion in Mismatched Minitransplants | July 2010 | August 2021 |
| NCT01050946 | Terminated | Phase 2 | Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit | July 2009 | March 2013 |
| NCT01090414 | Terminated | Phase 1/Phase 2 | An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study | March 22, 2010 | June 18, 2018 |
| NCT01121120 | Terminated | Phase 2 | Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients | June 2010 | December 2020 |
| NCT00455897 | Terminated | Phase 2 | CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma | December 2006 | July 2011 |
| NCT01186458 | Terminated | Phase 2 | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | October 2010 | October 2013 |
| NCT00432419 | Terminated | Phase 1/Phase 2 | Therapeutic Intensification of HIV-associated Non-Hodgkin's Lymphoma by Peripheral Blood Cell Transplantation Following Chemotherapy. | February 2007 | October 2008 |
| NCT01232556 | Terminated | Phase 3 | A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy | April 4, 2011 | March 28, 2014 |
| NCT00413959 | Terminated | Phase 2 | VELCADE,Rituximab,Cyclophosphamide and Decadron | August 2006 | January 2011 |
| NCT04342117 | Terminated | Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL | April 23, 2020 | December 31, 2020 | |
| NCT00367497 | Terminated | Phase 2 | Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma | August 2005 | November 2007 |
| NCT01555853 | Terminated | Phase 1 | Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma | July 2012 | June 2016 |
| NCT00354822 | Terminated | Phase 2 | Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas. | August 2005 | August 2009 |
| NCT00275262 | Terminated | Phase 2 | A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation | February 2006 | |
| NCT01745354 | Terminated | Phase 1 | Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) | August 2012 | November 2014 |
| NCT00000723 | Terminated | N/A | The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer | March 1990 | |
| NCT00578461 | Terminated | N/A | T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE | October 2007 | May 2013 |
| NCT02065869 | Terminated | Phase 1/Phase 2 | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | April 2014 | September 7, 2021 |
| NCT02376699 | Terminated | Phase 1 | Safety Study of SEA-CD40 in Cancer Patients | February 28, 2015 | April 14, 2023 |
| NCT02417129 | Terminated | Phase 3 | BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma | April 2015 | December 2015 |
| NCT02440685 | Terminated | Phase 1/Phase 2 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | May 2015 | July 2018 |
| NCT01490957 | Unknown status | Functional Assessment of Cancer Therapy - Bone Marrow Transplant | March 2008 | ||
| NCT03244930 | Unknown status | Phase 2 | Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation | May 10, 2017 | June 10, 2018 |
| NCT01148173 | Unknown status | Phase 2 | High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas | October 2007 | October 2012 |
| NCT00538551 | Unknown status | Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases | January 2007 | July 2015 | |
| NCT04083079 | Unknown status | Phase 4 | Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma | August 1, 2019 | April 1, 2022 |
| NCT02836639 | Unknown status | Phase 2 | BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma | February 2016 | |
| NCT00324467 | Unknown status | Phase 2 | Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment | August 2006 | December 2021 |
| NCT00333008 | Unknown status | Phase 2 | A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. | May 2006 | |
| NCT05557903 | Unknown status | Phase 1 | Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL | December 20, 2021 | June 30, 2023 |
| NCT02431403 | Unknown status | Phase 1/Phase 2 | ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma | February 2015 | |
| NCT04638270 | Unknown status | Early Phase 1 | Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL | November 21, 2020 | November 1, 2023 |
| NCT01843868 | Unknown status | N/A | Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP | May 2013 | December 2015 |
| NCT03921879 | Unknown status | Phase 1 | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma | July 29, 2019 | June 2021 |
| NCT00154440 | Unknown status | Phase 3 | Helicobacter - Lymphoma - Radiation Part I: Eradication, Part II: Radiation | November 2001 | October 2013 |
| NCT03765593 | Unknown status | Biomarkers in Primary Sjögren's Syndrome | March 2019 | March 2021 | |
| NCT03373019 | Unknown status | Phase 2 | Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | December 21, 2017 | March 1, 2021 |
| NCT00538096 | Withdrawn | Phase 1 | A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma | September 2007 | May 2010 |
| NCT05431179 | Withdrawn | Phase 3 | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | March 2023 | December 2026 |
| NCT03772288 | Withdrawn | Phase 1 | A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) | April 3, 2019 | November 17, 2021 |
| NCT03369964 | Withdrawn | Phase 1 | A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | March 14, 2018 | August 31, 2019 |
| NCT00319332 | Withdrawn | Phase 3 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen | September 2005 | February 2021 |
| NCT02298816 | Withdrawn | B-Cell Hematologic Malignancy Vaccination Registry | August 2014 | December 2025 | |
| NCT01263418 | Withdrawn | Phase 2 | Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas | June 2011 | January 2018 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D008228